Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among US men who have sex with men

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages

  Mansergh, Gordon ^a   Koblin, Beryl A ^b   Colfax, Grant N ^c   McKirnan, David J ^d   Flores, Stephen A ^a   Hudson, Sharon M ^e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Health Research Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG EFFICACY; DRUG USE; ETHNICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE HOMOSEXUAL; PRIORITY JOURNAL; RACE; SEXUAL TRANSMISSION; UNITED STATES; UNSAFE SEX; VIRUS TRANSMISSION; ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; HIV INFECTIONS; MALE; MALE HOMOSEXUALITY; SERODIAGNOSIS; SEXUAL BEHAVIOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; SEXUAL BEHAVIOR; YOUNG ADULT;

EID: 77957300389     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f27616     Document Type: Letter

References (12)

1. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group: Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22: 1463-1473.
2. Greenbaum A, Wilson LE, Keruly JC, et al. Effect of age and HAART regimen on clinical response in an urban cohort of HIV infected individuals. AIDS. 2008;22:2331-2339.
3. Patterson K, Napravnik S, Eron J, et al. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med. 2007;8:406-410.
4. Silverberg MJ, Leyden W, Horberg MA, et al. Quesenberry: older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007;167:684-691.
5. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537-544.
6. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age: results from the French Hosp Database on HIV. AIDS. 2004;18:2029-2038.
7. Nogueras, M, Navarro G, Anton E, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis. 2006;6:159.
8. Bonnet F, Thiebaut R, Chene G, et al. Determinants of clinical progression in antiretroviral na'?ve HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med. 2005;6:198-205.
9. Rebecca KL, Colette JS, Mike Y, et al. Phillips: stability of antiretroviral regimens in patients with viral suppression. AIDS. 2008;22:1039-1046.
10. Gebo KA, Fleishman JA, Moore RD. Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr. 2005;40: 609-616.
11. Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7:549-557.
12. Shah SS, McGowan JP, Smith C, et al. Klein: comorbid conditions, treatment, and health maintenance in older persons with Human Immunodeficiency Virus infection in New York City. Clin Infect Dis. 2002;35:1238-1243.